<DOC>
	<DOC>NCT03051945</DOC>
	<brief_summary>Demonstrate the acute effects of ketamine on endogenous µ-opioid neurotransmission in humans.</brief_summary>
	<brief_title>Endogenous Opioid Modulation by Ketamine</brief_title>
	<detailed_description>This study will test the hypothesis that the rapidly-acting antidepressant ketamine improves core depressive symptoms by acutely activating the brain's endogenous µ-opioid system.</detailed_description>
	<mesh_term>Depressive Disorder</mesh_term>
	<mesh_term>Depression</mesh_term>
	<mesh_term>Depressive Disorder, Major</mesh_term>
	<mesh_term>Ketamine</mesh_term>
	<mesh_term>Endorphins</mesh_term>
	<criteria>age 1865 diagnosis of DSMIV/DSM5 major depressive disorder current moderatetosevere depressive episode Patient Health Questionnaire (PHQ9) total score ≥ 10 PHQ9 item score ≥ 2 on "Little interest or pleasure" PHQ9 item score ≥ 2 on "Feeling down, depressed, or hopeless" medical documentation of depression for at least 2 months chronic depression: current episode duration &gt;2 years high medication resistance: nonresponse to &gt;3 adequate trials in the current episode moderatetosevere DSM5 substance use disorder (past year) cognitive disorder (lifetime) posttraumatic stress disorder (past year) obsessive compulsive disorder (past year) personality disorder (past year) positive urine drug screen history of psychotic symptoms significant neurologic disorder or injury breastfeeding or pregnancy imminent suicide risk unstable psychiatric or medical condition requiring a higher level of care contraindication to ketamine, MRI, or PET</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>65 Years</maximum_age>
	<verification_date>March 2017</verification_date>
</DOC>